VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash

The agreement defers November and December repayments while leaving those amounts in outstanding principal.

Rhea-AI Summary

VolitionRx (VNRX) made a $500,000 cash partial prepayment on its senior secured convertible note issued to Lind Global Asset Management XII.

The payment reduced the balance on the originally $2.4 million note to $706,667. Debt reduction across both Lind notes exceeds $5.0 million since June 30, 2026; the originally $7.5 million note was fully satisfied in September. Lind agreed not to exercise conversion rights on or prior to January 1, 2027, unless and until the closing share price equals or exceeds $0.275. November and December 2026 repayments were deferred but remain outstanding principal. Volition expects to fully satisfy the remaining note well before maturity.

5 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointOver $5.0 million in debt extinguished across both Lind notes since June 30, 2026. 96% of market cap
• Moderate point$500,000 cash prepayment reduced the originally $2.4 million note balance to $706,667. 9.6% of market cap
• Moderate pointConversion rights paused on or prior to January 1, 2027, subject to the share-price exception.
• Moderate pointNovember and December 2026 repayments deferred, postponing required cash payments.
• Minor point. Forward-looking: it has not happened yet and may not happen.Remaining note repayment expected by Volition well before maturity.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.$0.275 closing share price can end the agreed conversion pause.
• Minor pointDeferred November and December repayments remain outstanding principal until satisfied.

News Explained

At June 30, 2026, reported cash and equivalents were $2.8 million; measured against second-quarter operating cash outflow, that balance equaled 49.4 days of outflow—a historical liquidity comparison, not a post-payment cash figure.

Sources and calculations

• VolitionRx second-quarter 2026 fundamentals (2026Q2)

• Available liquidity against the last reported quarterly operating outflow, in days at that rate $2,800,000 / ($5,159,649 / 91) = 49.4 days

Argus 15 min delay 12 alerts

+7.28% vs previous close $0.19 last price 75.3x rel. volume Open Argus

Details

Market move: VNRX +7.28% vs previous close. Convertible note prepayment

$0.18 – $0.20 Day Range

$5.61M Mkt Cap at Last Price

On Oct 27, the day this news came out, the latest delayed price for VNRX is 7.28% above the previous close. Our momentum scanner has recorded 12 alerts for this stock so far that day. The latest delayed price is $0.19. Relative volume is exceptionally heavy at 75.3x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Cash prepayment: $500,000 Remaining note balance: $706,667 Debt reduction across both notes: Over $5.0 million +2 more

Cash prepayment

$500,000

Partial prepayment of the outstanding note principal

Remaining note balance

$706,667

Outstanding after the partial prepayment

Debt reduction across both notes

Over $5.0 million

Since June 30, 2026

Conversion price threshold

$0.275 per share

Conversion rights paused through Jan. 1, 2027, unless the closing share price reaches the threshold

Deferred monthly repayments

November and December 2026

Remaining monthly repayments deferred and reflected in outstanding principal

Historical Context

1 past event · Latest: Sep 14

1 event

1. Sep 14

   Debt repayment

   24h Move

   +0.6%

   Paid off the $7.5 million Lind note; a separate $2.4 million note remained outstanding.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

convertible promissory note

1 terms

convertible promissory note financial

"its senior secured convertible promissory note, dated January 15, 2026"

A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Reduces outstanding principal to only $0.7 million on the $2.4 million note and brings total debt reduction across both notes to over $5.0 million since June 30, 2026.
• Secures agreement pausing conversion rights until January 2027 (unless closing share price equals or exceeds $0.275) and deferring remaining monthly repayments for 2026.

HENDERSON, Nev., Oct. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a $500,000 partial prepayment in cash towards the outstanding principal balance on its senior secured convertible promissory note, dated January 15, 2026, in the original principal amount of $2,400,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the partial pre-payment, the remaining outstanding balance under the Note as of the date of this announcement is down to $706,667. As previously announced, the senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000, also issued to Lind, was fully-satisfied by the Company in September and is no longer outstanding.

In connection with the partial prepayment, Volition and Lind entered into a waiver and consent pursuant to which (i) Lind agreed to accept such prepayment, (ii) Lind agreed not to exercise its conversion rights under the Note on or prior to January 1, 2027 unless and until the closing price per share of Volition's common stock equals or exceeds $0.275 per share, and (iii) the parties agreed to defer the otherwise required monthly repayments for each of November and December 2026 and to continue to reflect such amounts in outstanding principal until otherwise satisfied.

Cameron Reynolds, Chief Executive Officer, Volition, commented:

"We appreciate Lind's continued partnership and flexibility as reflected in this agreement and are very pleased to prepay a significant portion of the outstanding balance of this Note to Lind in cash well ahead of schedule. With this prepayment, we have extinguished over $5.0 million across both notes since June 30^th, and we expect to have the remaining Note fully-satisfied well in advance of its maturity. We continue to execute against our plan to improve Volition's financial position and further debt and expense reduction remains a top priority as we seek to maximize stockholder value."

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Ellen Amonoo, Volition, mediarelations@volition.com 

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements reflect the current belief and expectations of management and relate to, among other topics, statements regarding the satisfaction of the remaining obligations under the Note prior to the scheduled maturity date, as well as future reductions of debt and expenses. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Volition believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are subject to risks and uncertainties that may cause Volition's actual activities or results to differ materially from those indicated or implied by any forward- looking statement, including, without limitation, due to risks and uncertainties related to risks disclosed in the documents Volition files from time to time with the SEC, including Volition's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-500-000-partial-pre-payment-of-convertible-note-in-cash-302920531.html

SOURCE VolitionRx Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much convertible debt remains after VolitionRx's cash prepayment?

The remaining balance on VolitionRx's originally $2,400,000 Lind note is $706,667 following the $500,000 cash prepayment. The separate, originally $7,500,000 Lind note was fully satisfied in September and is no longer outstanding.

What are the terms of VolitionRx's Lind conversion pause?

Lind agreed not to exercise conversion rights on or prior to January 1, 2027, unless and until VolitionRx's closing share price equals or exceeds $0.275. The agreement also defers the required November and December 2026 repayments, which remain outstanding principal until satisfied.